Looks like Governor Douchebag has had his little 15 minutes of fame. The idea of rigging the dnc convention to move Biden out and stuff Cuomo in there offered a little hemorrhoidal relief to the dems for a week or two but then the kool aid lost its potency. Not going to be their last little desperate fantasy though. Chris Cuomo’s ratings plummet as Americans tire of brothers’ schtick https://nypost.com/2020/05/30/chris-cuomos-ratings-plummet-as-brothers-schtick-gets-old/
Actually the reason to post the Salon article is that it is trying to connect the action taken from the Trump administration to deregulate nursing home requirements to the COVID-19 outbreaks. My read is that the assertions pushed in this Salon article are quite a stretch. I wanted to see what others thought who read the article. The reality is that most nursing homes are thinly staffed and not prepared for something of the magnitude of a COVID-19 breakout -- even when Obama was in office. Cuomo should have taken direct responsibility for placing elderly patients back into nursing homes. Part of the reality is "where else can they go?" Many have no family that can care for them when they are released from the hospitals. Cuomo lost a lot of support due to his trying to pass off the blame regarding nursing homes. It should have been his moment to say the "buck stops here" and further enhance the reputation he was building during the COVID-19 response. Instead he simply sunk his stature back to where it was pre-COVID.
Somebody better tell this guy that hydroxychloroquine + azithromycin doesn't work and possibly kills people. He is at Yale. That makes sense. Only idiots are at Yale. I mean can this epidemiologist not read studies like the journalist at CNN and MSNBC? https://medicine.yale.edu/profile/harvey_risch/ Dr. Harvey Risch is Professor of Epidemiology in the Department of Epidemiology and Public Health at the Yale School of Public Health and Yale School of Medicine. Dr. Risch received his MD degree from the University of California San Diego and PhD from the University of Chicago. After serving as a postdoctoral fellow in epidemiology at the University of Washington, Dr. Risch was a faculty member in epidemiology and biostatistics at the University of Toronto before coming to Yale. https://www.ncbi.nlm.nih.gov/research/coronavirus/publication/32458969 Early Outpatient Treatment of Symptomatic, High-Risk Covid-19 Patients that Should be Ramped-Up Immediately as Key to the Pandemic Crisis. An outpatient treatment that prevents hospitalization is desperately needed. Two candidate medications have been widely discussed: remdesivir, and hydroxychloroquine+azithromycin. Remdesivir has shown mild effectiveness in hospitalized inpatients, but no trials have been registered in outpatients. Hydroxychloroquine+azithromycin has been widely misrepresented in both clinical reports and public media, and outpatient trials results are not expected until September. Early outpatient illness is very different than later hospitalized florid disease and the treatments differ. Evidence about use of hydroxychloroquine alone, or of hydroxychloroquine+azithromycin in inpatients, is irrelevant concerning efficacy of the pair in early high-risk outpatient disease. Five studies, including two controlled clinical trials, have demonstrated significant major outpatient treatment efficacy. Hydroxychloroquine+azithromycin has been used as standard-of-care in more than 300,000 older adults with multicomorbidities, with estimated proportion diagnosed with cardiac arrhythmias attributable to the medications 47/100,000 users, of which estimated mortality is <20%, 9/100,000 users, compared to the 10,000 Americans now dying each week. These medications need to be widely available and promoted immediately for physicians to prescribe.
I put this here without the slightest claim that it is true or untrue. I remember just a couple months ago people could have different views on covid and place them online. Not sure that is still true. Might be a knock at my door or something or the Fauci-Zuckerman Truth Squad might report me to Don Lemon or however it works. These doctors might be disowned and smeared by WHO because WHO deals only in facts and the truth (little joke there, not all that funny though when you think of the devastation those clowns have enabled). COVID-19 becoming much less lethal, Italian doctors say https://www.dailysabah.com/world/europe/covid-19-becoming-much-less-lethal-italian-doctors-say
Plasma Super-Donors Inside a convalescent plasma therapy program treating coronavirus patients https://www.cbsnews.com/news/coronavirus-antibodies-blood-plasma-therapy-60-minutes-2020-05-31/
And it's Wuhan for the win!!! In a post-coronavirus world, China looks set to grow while the rest of the world contracts In the face of a global recession, China looks set to be one of the few countries that will expand, economically and politically, analysts say. https://www.cnbc.com/2020/06/01/aft...-to-grow-as-world-braces-for-contraction.html
So there continues to be this/below. I like the way that they are positioning themselves to be in high gear and hit the ground running if it works. Of course they don't know if it works yet and we can agree that that is sort of an important question. ya think? AstraZeneca is aiming to produce 2 billion doses of a coronavirus vaccine — and it could be ready by September Pharmaceutical company AstraZeneca is aiming to produce 2 billion doses of a coronavirus vaccine, including 400 million for the U.S. and U.K. and 1 billion for those in low- and middle-income countries. It plans to start distributing the vaccine to the U.S. and U.K. in September or October, with the balance of deliveries likely to be made by early 2021, according to AstraZeneca CEO Pascal Soriot, on a call with journalists Thursday. AstraZeneca said it had signed a licensing deal with the Serum Institute of India to provide 1 billion doses to low- and middle-income countries, with 400 million of those shots set to be delivered by the end of 2020, according to a press release Thursday. The vaccine, named AZD1222, was originally developed by Oxford University in the U.K. and AstraZeneca is working with pharmaceutical industry partners to manufacture and distribute the drug. Soriot said the distribution was dependent on clinical trials taking place by August. Clinical trials and manufacturing are set to occur concurrently, which is an unprecedented move for the pharmaceutical industry because of the risk of producing a drug that might not work. “We are very focused and very committed. When you have something like this with this sort of pandemic and the tremendous impact it has on people, the economy, et cetera, you can’t second-guess what’s going to happen. You can’t spend your time figuring out is it going to work or not going to work, you just have to commit. … We come in and make a bet on some of these things,” Soriot said on the call. AstraZeneca ✔@AstraZeneca https://www.cnbc.com/2020/06/04/ast...o-billion-doses-of-a-coronavirus-vaccine.html
The US government's supply of remdesivir — the only drug proved to treat the coronavirus — is due to run out at the end of June https://www.businessinsider.com/rem...atment-us-govt-shipments-ending-gilead-2020-6 The US government is on pace to run out of remdesivir drugs at the end of June and does not know when it will get more. The Department of Health and Human Services told CNN that Gilead, which makes the drug, will ship a final batch on the week of June 29. "We're waiting to hear from Gilead what is their expected delivery availability of the drug as we go from June to July," Dr. Robert Kadlec told the network. Remdesivir is the only widely approved COVID-19 treatment, and early studies found it helped mitigate the effect of the virus. All 1.5 million vials of remdesivir that Gilead has in stock are in circulation. Gilead says it will get new stocks of crucial raw materials to make more in July. Dr. Robert Kadlec, an HHS official, told CNN that Gilead Sciences, which created the drug, is scheduled to send the government a final shipment the week of June 29, but after that the HHS does not know when it will get more. "We're waiting to hear from Gilead what is their expected delivery availability of the drug as we go from June to July," Kadlec said. The US government received 607,000 vials of the drug in early May, which it planned to use over six weeks on 78,000 patients in the worst-hit states. Gilead has so far donated 1.5 million vials of the drug worldwide. That is all it has in stock so far. It is uncertain when the US will be able to get more after the final batch runs out. Gilead says it will be able to produce more remdesivir starting in July, when the raw materials needed to make the drug — which it had ordered in January — are expected to arrive. The US Food and Drug Administration hurriedly approved remdesivir as a coronavirus treatment on May 1, and preliminary studies indicate it has a marked impact on the health of those infected. Scientists found that the benefits appeared much greater for those with less severe symptoms, however, and aren't sure whether it can reduce coronavirus deaths, STAT reported. The drug was first manufactured in 2009 to treat victims of the Ebola outbreak but was unsuccessful. It is clear that there is a shortage of the drug in the US. An investigation by The Wall Street Journal, published last Friday, found that the number of US patients requiring the drug outnumbered available supplies by two to one. "There's definitely not enough drug for the number of patients who we currently have and probably will have through August, when we may get more drug from Gilead," Michael Ison, a professor of medicine at Northwestern University, told The Journal. The drug, which is administered intravenously, is the leading hope for an approved COVID-19 treatment. Remdesivir has been approved for use on coronavirus patients in the UK, India, Taiwan, and Japan, and regulators in Australia are evaluating the drug. Gilead is yet to put a price tag on remdesivir, but the drug could generate $7 billion in sales by 2022, the investment bank SVB Leerink said last week. An alternative treatment, hydroxychloroquine, is another option under consideration and has been touted by President Donald Trump. The drug has FDA approval to treat malaria but has yet to be proved safe or effective as a coronavirus treatment.